Boehringer Ingelheim v. Granules India: Consent Judgment Blocks Generic Jardiance®
Boehringer Ingelheim sued Granules India in the Delaware District Court over four patents covering empagliflozin (Jardiance®) 10 and 25 mg tablets. The case resolved via consent judgment in 96 days, enjoining Granules from commercializing its ANDA product in the United States until all four patents expire — a full market-exclusivity lock that typically signals a patent-term licensing or settlement arrangement reached before any merits ruling.
Hatch-Waxman ANDA dispute ends in full injunction via consent judgment
Boehringer Ingelheim filed suit on 29 May 2025 in the District of Delaware against Granules India Limited, asserting infringement of four U.S. patents — US9949998B2, US11833166B2, US10258637B2, and US11090323B2 — arising from Granules’ submission of an Abbreviated New Drug Application (ANDA) for generic 10 mg and 25 mg empagliflozin tablets, referencing Boehringer’s blockbuster SGLT-2 inhibitor Jardiance®. The four patents span empagliflozin formulation, composition, and therapeutic-use claims across a multi-year application family.
The case closed on 2 September 2025, just 96 days after filing, via a consent judgment entered by Judge Colm F. Connolly. The consent judgment declares all four patents valid and enforceable with respect to Granules’ ANDA product, finds that commercialization by Granules would constitute infringement, and enters a permanent injunction blocking Granules — and any successors, assigns, or affiliates — from making, selling, offering to sell, importing, or distributing the ANDA product in the United States through the expiration of each patent, including any patent term extensions or pediatric exclusivity. Boehringer Ingelheim Corporation was separately dismissed with prejudice as a named plaintiff, suggesting entity restructuring rather than a merits concession.
Resolution in under 100 days — before any claim construction briefing would typically be complete — is consistent with a negotiated outcome, likely involving a confidential authorized-generic or entry-date agreement appended to the consent judgment. The public record is silent on any licensed entry date or royalty arrangement, which are standard non-public elements of Hatch-Waxman settlements. The breadth of the injunction, extending to patent term adjustments and pediatric exclusivity, suggests Boehringer sought maximum protective language, and Granules’ acceptance without cost-shifting or a merits fight may reflect commercial pragmatism given Jardiance®’s multi-billion-dollar annual revenues.
Filing to Consent Judgment in 96 days
96 days — resolved significantly faster than the median ANDA Hatch-Waxman trial in Delaware
Consent judgment entered: what the injunction means for both parties
Consent judgment — agreed injunction, no merits trial
A consent judgment is a court-entered order reflecting a negotiated resolution. Here, both parties agreed that the four empagliflozin patents are valid, enforceable, and would be infringed by Granules’ ANDA product. No court ruled on the merits. The injunction has the full force of a litigated order, and the court retains jurisdiction to enforce it — including for preliminary injunctive relief against breach.
Agreed order — full injunctive forceBoehringer secures full exclusivity through patent expiry
Boehringer obtained a permanent injunction covering all four patents, including any patent term extensions, adjustments, and pediatric exclusivity periods. The order also preserves Boehringer’s ability to apply for court modification if additional regulatory exclusivities are granted. This is an expansive and durable outcome that forecloses Granules’ independent commercial launch absent separate authorization — which may exist under a confidential side agreement not visible in the public record.
Full exclusivity preservedGranules enjoined — potential licensed entry date not public
Granules India accepted the consent judgment without litigating validity or non-infringement. The public order permanently blocks independent commercialization through patent expiry. However, the consent judgment expressly contemplates that Granules may be ‘specifically authorized’ by Boehringer — strongly suggesting a confidential licensing or authorized-generic arrangement may govern any future Granules entry. The terms of that arrangement, if any, are not disclosed in the public docket.
Independent launch blockedFour-patent wall reinforced around Jardiance® SGLT-2 franchise
The consent judgment strengthens Boehringer’s IP perimeter around empagliflozin by establishing court-entered validity findings against a generic challenger. Other ANDA filers targeting Jardiance® should note that the ‘998, ‘166, ‘637, and ‘323 patents now carry an additional layer of enforceability. The 96-day resolution without cost-shifting suggests generic challengers may face a high commercial bar when litigating against a well-resourced innovator protecting a blockbuster SGLT-2 inhibitor franchise.
Reinforced market exclusivityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Pharmaceutical innovator — holder of US9949998B2, US11833166B2, US10258637B2, and US11090323B2 covering empagliflozinSearch in Eureka ↗ |
| Defendant | Granules India Limited | Individual | Indian generic pharmaceutical manufacturer; filed ANDA for 10 mg and 25 mg empagliflozin tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notable for its explicit validity and enforceability findings — unusual in a negotiated resolution, where such findings are sometimes omitted to limit precedential exposure. By agreeing that the ‘998, ‘166, ‘637, and ‘323 patents are valid and enforceable as to the ANDA product, Granules has effectively accepted a merits-equivalent record that could complicate future invalidity arguments by Granules or its affiliates in related proceedings. The separate dismissal with prejudice of Boehringer Ingelheim Corporation (as distinct from the Boehringer Ingelheim entity that remains party) suggests the plaintiff-side corporate structure was clarified as part of the agreed terms.
US9949998B2, US11833166B2, US10258637B2 & US11090323B2 — Empagliflozin formulation patents
The four asserted patents — US9949998B2 (appl. US14/918727), US11833166B2 (appl. US17/344003), US10258637B2 (appl. US15/918401), and US11090323B2 (appl. US16/288192) — form a multi-generation family protecting empagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. The staggered application dates across the family suggest continuation or continuation-in-part relationships, each adding or refining claims around the active molecule, formulation, and therapeutic uses.
Jardiance® (empagliflozin) generated approximately $7 billion in annual global revenues at the time of filing, making this patent family among the most commercially significant currently litigated in the Hatch-Waxman ANDA space. The consent judgment’s coverage of the full patent family — including term adjustments and pediatric exclusivity — suggests Boehringer views the downstream exclusivity period as commercially material. Competitors or follow-on ANDA filers targeting empagliflozin should treat the four patents as a reinforced cluster following the court-entered validity findings in this consent judgment.
Should you run an FTO against the Jardiance® empagliflozin patent family?
Any company developing or commercializing empagliflozin formulations, SGLT-2 inhibitor tablets, or competing ANDA products in the United States should conduct a freedom-to-operate analysis against this four-patent cluster. The consent judgment entered here creates court-acknowledged validity findings that, while not technically binding on third parties, signal robust enforceability. Generic manufacturers, authorized-generic partners, and biosimilar-adjacent formulation teams working in the SGLT-2 space face material infringement exposure if Orange Book-listed claims are not fully mapped against their product specifications.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US9949998B2, US11833166B2, US10258637B2, and US11090323B2 against a target product’s formulation and method of use, identify prosecution history estoppel, flag continuation applications still pending in the family, and surface prior art relevant to any invalidity reserve. For ANDA filers and generic pharmaceutical R&D teams, running a structured FTO before Paragraph IV certification filing is the most cost-effective risk-mitigation step available.
Run a freedom-to-operate analysis on US11833166B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA empagliflozin and SGLT-2 inhibitor patent cases in Delaware
Cases involving Hatch-Waxman ANDA challenges to SGLT-2 inhibitor patents litigated in the Delaware District Court before Judge Connolly.
What this case signals for the SGLT-2 inhibitor and ANDA litigation IP landscape
Boehringer’s rapid consent judgment outcome illustrates how innovators can efficiently reinforce blockbuster drug exclusivity against early generic entrants.
Multi-patent stacking remains the dominant Hatch-Waxman defence strategy
Boehringer asserted four patents across different application families covering empagliflozin. This layered approach means a generic challenger must successfully invalidate or design around every patent — not just one. Companies building ANDA defence or prosecution strategies in the SGLT-2 space should audit the full application family behind each Orange Book-listed patent, not only the compound patent.
Consent judgments under 100 days typically signal a confidential entry-date deal
When an ANDA case resolves before claim construction via consent judgment, it almost always reflects a private licensing arrangement fixing an authorized entry date. IP and commercial teams tracking Jardiance® generic timelines should monitor FDA’s Paragraph IV certification records and any future ANDA approval notifications to triangulate when Granules may be permitted to launch.
Boehringer-Ingelheim v Granules — key questions answered
The consent judgment entered in Case No. 1:25-cv-00663 (D. Del.) declares the ‘998, ‘166, ‘637, and ‘323 empagliflozin patents valid and enforceable, finds that Granules’ ANDA product would infringe each, and permanently enjoins Granules from making, selling, or importing the product in the United States until all four patents expire, including any patent term extensions or pediatric exclusivity periods.
The consent judgment dismisses Boehringer Ingelheim Corporation with prejudice as a named plaintiff. The public record does not explain the rationale, but this is consistent with a corporate-entity clarification — distinguishing the U.S. subsidiary from the operative plaintiff entity — rather than any merits concession. The remaining Boehringer entity continues as the enjoining party.
Four patents were asserted in this case: US9949998B2 (appl. US14/918727), US11833166B2 (appl. US17/344003), US10258637B2 (appl. US15/918401), and US11090323B2 (appl. US16/288192). These cover empagliflozin formulation compositions and therapeutic methods and are Orange Book-listed for Jardiance® 10 mg and 25 mg tablets. Additional patents may also be listed in the Orange Book.
The consent judgment explicitly preserves the possibility that Boehringer may ‘specifically authorize’ Granules to commercialize its ANDA product, suggesting a confidential licensing or authorized-generic arrangement may govern any future Granules entry. The terms of such an arrangement are not public. Absent Boehringer’s authorization, Granules is enjoined through patent expiry, including any extensions.
The injunction expressly extends to any pediatric exclusivity periods Boehringer may obtain, which are typically six-month add-ons granted by the FDA for conducting pediatric clinical studies. By including this language, Boehringer ensured that Granules cannot launch even during any post-patent pediatric exclusivity window, closing a potential entry gap that sometimes arises in ANDA settlements that reference only patent expiration dates.
PatSnap Eureka searches patents and litigation data to answer instantly.